These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 38502148)

  • 1. Viloxazine extended-release capsules as an emerging treatment for attention-deficit/hyperactivity disorder in children and adolescents.
    Maletic V; Mattingly GW; Earnest J
    Expert Rev Neurother; 2024 May; 24(5):443-455. PubMed ID: 38502148
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Viloxazine Extended-Release Capsules in Adults with Attention-Deficit/Hyperactivity Disorder.
    Nasser A; Hull JT; Chaturvedi SA; Liranso T; Odebo O; Kosheleff AR; Fry N; Cutler AJ; Rubin J; Schwabe S; Childress A
    CNS Drugs; 2022 Aug; 36(8):897-915. PubMed ID: 35896943
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An Open-Label Extension Study Assessing the Long-Term Safety and Efficacy of Viloxazine Extended-Release Capsules in Adults with Attention-Deficit/Hyperactivity Disorder.
    Childress A; Cutler AJ; Adler LA; Fry N; Asubonteng K; Maldonado-Cruz Z; Formella A; Rubin J
    CNS Drugs; 2024 Nov; 38(11):891-907. PubMed ID: 39373844
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Response of peer relations and social activities to treatment with viloxazine extended-release capsules (Qelbree
    Faraone SV; Gomeni R; Hull JT; Busse GD; Lujan B; Rubin J; Nasser A
    Brain Behav; 2023 Apr; 13(4):e2910. PubMed ID: 36847750
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A post hoc analysis of the effect of viloxazine extended-release capsules on learning and school problems in children and adolescents with attention-deficit/hyperactivity disorder.
    Faraone SV; Gomeni R; Hull JT; Busse GD; Melyan Z; Rubin J; Nasser A
    Eur Child Adolesc Psychiatry; 2023 Mar; 32(3):491-499. PubMed ID: 34581911
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Extended-Release Viloxazine for the Treatment of Attention-Deficit Hyperactivity Disorder in School-Age Children and Adolescents.
    Raible H; D'Souza MS
    Ann Pharmacother; 2023 Dec; 57(12):1436-1448. PubMed ID: 37021356
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluating the pharmacokinetics of extended release viloxazine in the treatment of children with attention-deficit/hyperactivity disorder.
    Childress A; Burton S
    Expert Opin Drug Metab Toxicol; 2022 Jun; 18(6):357-366. PubMed ID: 35848085
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Viloxazine extended-release capsules for the treatment of attention-deficit/ hyperactivity disorder in adult patients.
    Childress A; Sottile R; Khanbijian S
    Expert Rev Neurother; 2023; 23(11):945-953. PubMed ID: 37846759
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Translating Attention-Deficit/Hyperactivity Disorder Rating Scale-5 and Weiss Functional Impairment Rating Scale-Parent Effectiveness Scores into Clinical Global Impressions Clinical Significance Levels in Four Randomized Clinical Trials of SPN-812 (Viloxazine Extended-Release) in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder.
    Nasser A; Kosheleff AR; Hull JT; Liranso T; Qin P; Busse GD; O'Neal W; Fava M; Faraone SV; Rubin J
    J Child Adolesc Psychopharmacol; 2021 Apr; 31(3):214-226. PubMed ID: 33600233
    [No Abstract]   [Full Text] [Related]  

  • 10. Executive Function Outcome of Treatment with Viloxazine Extended-Release Capsules in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Post-Hoc Analysis of Four Randomized Clinical Trials.
    Faraone SV; Gomeni R; Hull JT; Busse GD; Melyan Z; Rubin J; Nasser A
    Paediatr Drugs; 2021 Nov; 23(6):583-589. PubMed ID: 34523063
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predicting efficacy of viloxazine extended-release treatment in adults with ADHD using an early change in ADHD symptoms: Machine learning Post Hoc analysis of a phase 3 clinical trial.
    Faraone SV; Gomeni R; Hull JT; Chaturvedi SA; Busse GD; Melyan Z; O'Neal W; Rubin J; Nasser A
    Psychiatry Res; 2022 Dec; 318():114922. PubMed ID: 36375329
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of centanafadine in adults with attention-deficit/hyperactivity disorder: A matching-adjusted indirect comparison vs lisdexamfetamine dimesylate, atomoxetine hydrochloride, and viloxazine extended-release.
    Schein J; Cloutier M; Gauthier-Loiselle M; Catillon M; Xu C; Chan D; Childress A
    J Manag Care Spec Pharm; 2024 Jun; 30(6):528-540. PubMed ID: 38824626
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Extended-Release Viloxazine Compared with Atomoxetine for Attention Deficit Hyperactivity Disorder.
    Price MZ; Price RL
    CNS Drugs; 2023 Jul; 37(7):655-660. PubMed ID: 37430151
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent advances in pharmacological management of attention-deficit/hyperactivity disorder: moving beyond stimulants.
    Childress A
    Expert Opin Pharmacother; 2024 May; 25(7):853-866. PubMed ID: 38771653
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Phase II Double-Blind, Placebo-Controlled, Efficacy and Safety Study of SPN-812 (Extended-Release Viloxazine) in Children With ADHD.
    Johnson JK; Liranso T; Saylor K; Tulloch G; Adewole T; Schwabe S; Nasser A; Findling RL; Newcorn JH
    J Atten Disord; 2020 Jan; 24(2):348-358. PubMed ID: 30924702
    [No Abstract]   [Full Text] [Related]  

  • 16. Early response to SPN-812 (viloxazine extended-release) can predict efficacy outcome in pediatric subjects with ADHD: a machine learning post-hoc analysis of four randomized clinical trials.
    Faraone SV; Gomeni R; Hull JT; Busse GD; Melyan Z; O'Neal W; Rubin J; Nasser A
    Psychiatry Res; 2021 Feb; 296():113664. PubMed ID: 33418457
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Effect of Viloxazine Extended-Release Capsules on Functional Impairments Associated with Attention-Deficit/Hyperactivity Disorder (ADHD) in Children and Adolescents in Four Phase 3 Placebo-Controlled Trials.
    Nasser A; Hull JT; Liranso T; Busse GD; Melyan Z; Childress AC; A Lopez F; Rubin J
    Neuropsychiatr Dis Treat; 2021; 17():1751-1762. PubMed ID: 34113106
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Viloxazine: Pediatric First Approval.
    Lamb YN
    Paediatr Drugs; 2021 Jul; 23(4):403-409. PubMed ID: 34036533
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Phase III, Randomized, Placebo-controlled Trial to Assess the Efficacy and Safety of Once-daily SPN-812 (Viloxazine Extended-release) in the Treatment of Attention-deficit/Hyperactivity Disorder in School-age Children.
    Nasser A; Liranso T; Adewole T; Fry N; Hull JT; Chowdhry F; Busse GD; Cutler AJ; Jones NJ; Findling RL; Schwabe S
    Clin Ther; 2020 Aug; 42(8):1452-1466. PubMed ID: 32723670
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Viloxazine ER (Qelbree
    Kameg B
    J Psychosoc Nurs Ment Health Serv; 2022 Jul; 60(7):7-9. PubMed ID: 35858173
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.